SlideShare una empresa de Scribd logo
1 de 27
Make the right decisionswith data youcan trust
Instructionsforattendees Due to the High number of attendees:  Before starting  Use your full name for Identification We will mute your microphone during the webinar During the webinar Use the chat for questions At the End  You can ask your questions orally We will answer them either in the webinar session or later on by email. 07/04/2011 2 AurPASS
PredictingPharmacology & Safety Profiles Using AurPASS
	Agenda Aureus Sciences Knowledge-Based Pharmacological Profiling AurPROFILER: visualizing the Known  Filling the Gap using AurPASS to Predict the Unknown AurPASS PASS Predictive Algorithm Added Value of AurSCOPE Knowledgebases AurPASS Ion Channels & AurPASS Kinase Live Demo: Applications for Safety Pharmacology Assessment Discussion 07/04/2011 4 AurPASS
Aureus at a Glance Aureus is a knowledge and information management solutions provider for the Life Science industry located in Paris.  Over the past 10 years the company has developed a unique knowledge production platform which stores, indexes and organizes critical chemical and bioactivity information including experimental in vitro and in vivo protocols from the public or private literature. Aureus employees 20 highlevelscientists (PhD and MSc) includingscientific and IT project leaders and documentation analysts Aureus is funded by institutional investors like CDC Entreprise, AXA Provate Equity, OTC Asset Management and is part of the OSEO Excellence innovation team. 07/04/2011 5 AurPASS
		Aureus Approach
AurSCOPE  Knowledge Databases Target Pharmacological Space 2002 2004 2005 2008 2009 Nuclear  Receptor Protease GPCR Kinase Ion Channel Publications Analyzed   13,303 including    6,966 patents 32,588 including  15,281 patents 4,668 including 2,484 patents 4,226 including 1,060  patents 10,206 including  6,806 patents Biological Activities 275,044 418,202 186,047 1,243,793 670,407 98,439 354,323 146,426 Unique  Ligands 124,313 48,500 Biological Protocols Aureus Terminology, Glossary, Thesaurii >70 glossaries and dictionaries, 5-10 taxonomies, >65,000 terms and synonyms, IUPHAR, SwissPROT 07/04/2011 7 AurPASS
AurSCOPE Knowledge Databases ADME/DDI & TOX hERG ADME/DDI Hepatotox 12,165 including 200 FDA Reviews Publications Analyzed 2,291 including  547 Patents 3,600 Articles (67 patents, 75 FDA Studies) 70,035 Biological Activities 33,210 462,785 Unique  Ligands 13,887 34,872 compounds  including 4,050 metabolites 845 Drugs Biological Protocols Aureus Terminology, Glossary, Thesaurii >100 glossaries and dictionaries, 5-10 taxonomies, >65,000 terms and synonyms, IUPHAR, SwissPROT 07/04/2011 8 AurPASS
Make The Right Decision With Data You Can Trust AurPROFILER Data analysis & Navigation Medicinal Chemistry Space AurQUEST Data mining AurPASS Predict Biological  Activities Spectra DDI Predict AurPASS
AurPROFILER – Pharmacology Profiles of 74 Drugs (Big Pharma) 07/04/2011 10 AurPASS
Filling the Gap Using AurPASS in silicoPredictions 07/04/2011 11 Aureus Prediction of Activity Spectra for Substances AurPASS
Predicting New Activities on Selectedbig Pharma Drugs 277 Ion Channels 86SelectedMoleculesfrom MERCK 07/04/2011 12 AurPASS
Over Forty Publications with Independent Confirmation of PASS Predictions… 07/04/2011 13 AurPASS
		AurPASS Training Set SAR data extracted from individual AurSCOPE databases Chemical & biological post-processing Chemical Structures Multilevel Neighborhoods of Atoms (MNA) descriptors SAR Base Diverse chemical structures and associated MNA descriptors Associated qualitative biologicalactivity types Prediction Algorithm PASS Bayesian approach Models Validation LOO and L20%O validations External dataset 07/04/2011 14 AurPASS
Training Set SAR data extracted from individual AurSCOPEknowledgebases Chemical & biological post-processing Chemical Structures Multilevel Neighborhoods of Atoms (MNA) descriptors SAR Base Diverse chemical structures and associated MNA descriptors Associated qualitative biologicalactivity types Prediction Algorithm PASS Bayesian approach Models Validation LOO and L20%O validations External dataset AurPASS 07/04/2011 15 AurPASS
	Added Value of Structured Data for Predictive Models 07/04/2011 16 ChemicalProcessing ,[object Object]
 No mixtures
Inorganic and metalo-organicremoval
 Charge standardizationBiologicalProcessing ,[object Object]
Target hierarchy
Target species, celllinesand tissues
Biologicalactivityparameters
Ligand action on targetAurPASS
07/04/2011 17 AssigningActivity Classes AurPASSActivity Types AurPASS
Multilevel Neighbourhoods of Atoms (MNA) descriptors are generated on the basis of the connection table of 2D molecular structures (including hydrogens) Bond types are not specified MNA are generated as recursively defined  ,[object Object]
 The first level MNA descriptor include the atom’s zero level descriptors and zero-level descriptors of its neighboring atoms sorted lexicographically …  	Encoding Chemical Structures: MNA Descriptors 07/04/2011 18 MNA descriptorsdictionary AurPASS
	Encoding Chemical Structures: MNA Descriptors 07/04/2011 19 	MNA/2 C(C(CC-H)C(CC-C)-H(C)) C(C(CC-H)C(CN-H)-H(C)) C(C(CC-H)C(CN-H)-C(C-O-O)) C(C(CC-H)N(CC)-H(C)) C(C(CC-C)N(CC)-H(C)) N(C(CN-H)C(CN-H)) -H(C(CC-H)) -H(C(CN-H)) -H(-O(-H-C)) -C(C(CC-C)-O(-H-C)-O(-C)) -O(-H(-O)-C(C-O-O)) -O(-C(C-O-O)) MNA/0:   C MNA/1:   C(CN-H) MNA/2:   C(C(CC-H)N(CC)-H(C)) AurPASS

Más contenido relacionado

Similar a Webinar : Predicting Pharmacology and Safety Profiles with AurPASS

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global MarketsNucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
ReportsnReports
 
The perfect integration between Lab SOP and clinical strategy
The perfect integration between Lab SOP and clinical strategyThe perfect integration between Lab SOP and clinical strategy
The perfect integration between Lab SOP and clinical strategy
Sandro Esteves
 
Embase for pharmacovigilance: Search and validation March 22 2017
Embase for pharmacovigilance: Search and validation March 22 2017Embase for pharmacovigilance: Search and validation March 22 2017
Embase for pharmacovigilance: Search and validation March 22 2017
Ann-Marie Roche
 
Causes and consequences of automated extraction of patent-specified virtual d...
Causes and consequences of automated extraction of patent-specified virtual d...Causes and consequences of automated extraction of patent-specified virtual d...
Causes and consequences of automated extraction of patent-specified virtual d...
Chris Southan
 
II-SDV 2015, 20 - 21 April, in Nice
II-SDV 2015, 20 - 21 April, in NiceII-SDV 2015, 20 - 21 April, in Nice
II-SDV 2015, 20 - 21 April, in Nice
Dr. Haxel Consult
 
In silico 360 Analysis for Drug Development
In silico 360 Analysis for Drug DevelopmentIn silico 360 Analysis for Drug Development
In silico 360 Analysis for Drug Development
Chris Southan
 

Similar a Webinar : Predicting Pharmacology and Safety Profiles with AurPASS (20)

LAB MANUAL 2015
LAB MANUAL 2015LAB MANUAL 2015
LAB MANUAL 2015
 
Math 225-fall-2014
Math 225-fall-2014Math 225-fall-2014
Math 225-fall-2014
 
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global MarketsNucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
 
Recent advances toward preclinical and clinical translation of photoacoustic ...
Recent advances toward preclinical and clinical translation of photoacoustic ...Recent advances toward preclinical and clinical translation of photoacoustic ...
Recent advances toward preclinical and clinical translation of photoacoustic ...
 
Overview of SureChEMBL
Overview of SureChEMBLOverview of SureChEMBL
Overview of SureChEMBL
 
Math 225-spring-2012
Math 225-spring-2012Math 225-spring-2012
Math 225-spring-2012
 
The perfect integration between Lab SOP and clinical strategy
The perfect integration between Lab SOP and clinical strategyThe perfect integration between Lab SOP and clinical strategy
The perfect integration between Lab SOP and clinical strategy
 
Biotecnología
BiotecnologíaBiotecnología
Biotecnología
 
Embase for pharmacovigilance: Search and validation March 22 2017
Embase for pharmacovigilance: Search and validation March 22 2017Embase for pharmacovigilance: Search and validation March 22 2017
Embase for pharmacovigilance: Search and validation March 22 2017
 
Causes and consequences of automated extraction of patent-specified virtual d...
Causes and consequences of automated extraction of patent-specified virtual d...Causes and consequences of automated extraction of patent-specified virtual d...
Causes and consequences of automated extraction of patent-specified virtual d...
 
II-SDV 2015, 20 - 21 April, in Nice
II-SDV 2015, 20 - 21 April, in NiceII-SDV 2015, 20 - 21 April, in Nice
II-SDV 2015, 20 - 21 April, in Nice
 
DETECTORS USED IN HPLC
DETECTORS USED IN HPLCDETECTORS USED IN HPLC
DETECTORS USED IN HPLC
 
DETECTORS IN HPLC
DETECTORS IN HPLCDETECTORS IN HPLC
DETECTORS IN HPLC
 
Rapid diagnosis of infectious diseases
Rapid diagnosis of infectious diseasesRapid diagnosis of infectious diseases
Rapid diagnosis of infectious diseases
 
New Approach Methods - What is That?
New Approach Methods - What is That?New Approach Methods - What is That?
New Approach Methods - What is That?
 
In silico 360 Analysis for Drug Development
In silico 360 Analysis for Drug DevelopmentIn silico 360 Analysis for Drug Development
In silico 360 Analysis for Drug Development
 
neXtProt, a FAIR human protein resource working with the scientific community...
neXtProt, a FAIR human protein resource working with the scientific community...neXtProt, a FAIR human protein resource working with the scientific community...
neXtProt, a FAIR human protein resource working with the scientific community...
 
Enabling HTS Hit follow up via Chemo informatics, File Enrichment, and Outsou...
Enabling HTS Hit follow up via Chemo informatics, File Enrichment, and Outsou...Enabling HTS Hit follow up via Chemo informatics, File Enrichment, and Outsou...
Enabling HTS Hit follow up via Chemo informatics, File Enrichment, and Outsou...
 
SureChEMBL and Open PHACTS
SureChEMBL and Open PHACTSSureChEMBL and Open PHACTS
SureChEMBL and Open PHACTS
 
Novel Approaches to Elucidating Structure Activity Relationships
Novel Approaches to Elucidating Structure Activity RelationshipsNovel Approaches to Elucidating Structure Activity Relationships
Novel Approaches to Elucidating Structure Activity Relationships
 

Último

Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
MedicoseAcademics
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
 

Último (20)

Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptx
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
 
Integrated Neuromuscular Inhibition Technique (INIT)
Integrated Neuromuscular Inhibition Technique (INIT)Integrated Neuromuscular Inhibition Technique (INIT)
Integrated Neuromuscular Inhibition Technique (INIT)
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in children
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 

Webinar : Predicting Pharmacology and Safety Profiles with AurPASS

  • 1. Make the right decisionswith data youcan trust
  • 2. Instructionsforattendees Due to the High number of attendees: Before starting Use your full name for Identification We will mute your microphone during the webinar During the webinar Use the chat for questions At the End You can ask your questions orally We will answer them either in the webinar session or later on by email. 07/04/2011 2 AurPASS
  • 3. PredictingPharmacology & Safety Profiles Using AurPASS
  • 4. Agenda Aureus Sciences Knowledge-Based Pharmacological Profiling AurPROFILER: visualizing the Known Filling the Gap using AurPASS to Predict the Unknown AurPASS PASS Predictive Algorithm Added Value of AurSCOPE Knowledgebases AurPASS Ion Channels & AurPASS Kinase Live Demo: Applications for Safety Pharmacology Assessment Discussion 07/04/2011 4 AurPASS
  • 5. Aureus at a Glance Aureus is a knowledge and information management solutions provider for the Life Science industry located in Paris. Over the past 10 years the company has developed a unique knowledge production platform which stores, indexes and organizes critical chemical and bioactivity information including experimental in vitro and in vivo protocols from the public or private literature. Aureus employees 20 highlevelscientists (PhD and MSc) includingscientific and IT project leaders and documentation analysts Aureus is funded by institutional investors like CDC Entreprise, AXA Provate Equity, OTC Asset Management and is part of the OSEO Excellence innovation team. 07/04/2011 5 AurPASS
  • 7. AurSCOPE Knowledge Databases Target Pharmacological Space 2002 2004 2005 2008 2009 Nuclear Receptor Protease GPCR Kinase Ion Channel Publications Analyzed 13,303 including 6,966 patents 32,588 including 15,281 patents 4,668 including 2,484 patents 4,226 including 1,060 patents 10,206 including 6,806 patents Biological Activities 275,044 418,202 186,047 1,243,793 670,407 98,439 354,323 146,426 Unique Ligands 124,313 48,500 Biological Protocols Aureus Terminology, Glossary, Thesaurii >70 glossaries and dictionaries, 5-10 taxonomies, >65,000 terms and synonyms, IUPHAR, SwissPROT 07/04/2011 7 AurPASS
  • 8. AurSCOPE Knowledge Databases ADME/DDI & TOX hERG ADME/DDI Hepatotox 12,165 including 200 FDA Reviews Publications Analyzed 2,291 including 547 Patents 3,600 Articles (67 patents, 75 FDA Studies) 70,035 Biological Activities 33,210 462,785 Unique Ligands 13,887 34,872 compounds including 4,050 metabolites 845 Drugs Biological Protocols Aureus Terminology, Glossary, Thesaurii >100 glossaries and dictionaries, 5-10 taxonomies, >65,000 terms and synonyms, IUPHAR, SwissPROT 07/04/2011 8 AurPASS
  • 9. Make The Right Decision With Data You Can Trust AurPROFILER Data analysis & Navigation Medicinal Chemistry Space AurQUEST Data mining AurPASS Predict Biological Activities Spectra DDI Predict AurPASS
  • 10. AurPROFILER – Pharmacology Profiles of 74 Drugs (Big Pharma) 07/04/2011 10 AurPASS
  • 11. Filling the Gap Using AurPASS in silicoPredictions 07/04/2011 11 Aureus Prediction of Activity Spectra for Substances AurPASS
  • 12. Predicting New Activities on Selectedbig Pharma Drugs 277 Ion Channels 86SelectedMoleculesfrom MERCK 07/04/2011 12 AurPASS
  • 13. Over Forty Publications with Independent Confirmation of PASS Predictions… 07/04/2011 13 AurPASS
  • 14. AurPASS Training Set SAR data extracted from individual AurSCOPE databases Chemical & biological post-processing Chemical Structures Multilevel Neighborhoods of Atoms (MNA) descriptors SAR Base Diverse chemical structures and associated MNA descriptors Associated qualitative biologicalactivity types Prediction Algorithm PASS Bayesian approach Models Validation LOO and L20%O validations External dataset 07/04/2011 14 AurPASS
  • 15. Training Set SAR data extracted from individual AurSCOPEknowledgebases Chemical & biological post-processing Chemical Structures Multilevel Neighborhoods of Atoms (MNA) descriptors SAR Base Diverse chemical structures and associated MNA descriptors Associated qualitative biologicalactivity types Prediction Algorithm PASS Bayesian approach Models Validation LOO and L20%O validations External dataset AurPASS 07/04/2011 15 AurPASS
  • 16.
  • 19.
  • 23. Ligand action on targetAurPASS
  • 24. 07/04/2011 17 AssigningActivity Classes AurPASSActivity Types AurPASS
  • 25.
  • 26. The first level MNA descriptor include the atom’s zero level descriptors and zero-level descriptors of its neighboring atoms sorted lexicographically … Encoding Chemical Structures: MNA Descriptors 07/04/2011 18 MNA descriptorsdictionary AurPASS
  • 27. Encoding Chemical Structures: MNA Descriptors 07/04/2011 19 MNA/2 C(C(CC-H)C(CC-C)-H(C)) C(C(CC-H)C(CN-H)-H(C)) C(C(CC-H)C(CN-H)-C(C-O-O)) C(C(CC-H)N(CC)-H(C)) C(C(CC-C)N(CC)-H(C)) N(C(CN-H)C(CN-H)) -H(C(CC-H)) -H(C(CN-H)) -H(-O(-H-C)) -C(C(CC-C)-O(-H-C)-O(-C)) -O(-H(-O)-C(C-O-O)) -O(-C(C-O-O)) MNA/0: C MNA/1: C(CN-H) MNA/2: C(C(CC-H)N(CC)-H(C)) AurPASS
  • 28. PASS Approach for Biological Activity Prediction 07/04/2011 20 According to the Bayes' theorem, the probability P(A|S) that the compound S has activity (or inactivity) A, equals to: P(A|S) = P(S|A)•P(A)/P(S) If the descriptors of organic compound D1, ..., Dm are independent, then: P(S|A) = P(D1, ..., Dm|A) = ПiP(Di|A) P(A)andP(A|Di)are calculated as sums through all compounds of the training set: AurPASS Filimonov D.A., Poroikov V.V. (2008). Probabilistic Approach in Virtual Screening. In: Chemoinformatics Approaches to Virtual Screening. Alexander Varnek and Alexander Tropsha, Eds. RSC Publishing.
  • 29. The list of activities which are probable for a particular compound with the estimates for each activity of : Pa: probability to be active Pi: probability to be inactive Pa and Pi are calculated independently: Pa + Pi  1 Pa (Pi) can be considered as the probability of the compound belonging to classes of active (inactive) compounds PASS Approach for Biological Activity Prediction 07/04/2011 21 AurPASS
  • 30. AurPASS Ion Channels – Version 1.2.1 07/04/2011 22 Training Set 47 938 molecules 517 Activity Types Mean Accuracy of Prediction: 98% Test Set 2244 molecules 113 Activity types Mean Accuracy of Prediction: 90% AurPASS
  • 32. How AurPASS Works? 07/04/2011 24 Ion Channels Kinases GPCRs Proteases NuclearReceptors Off-Targets AurPASS
  • 33. AurPASS Ion Channels 07/04/2011 25 Live Demo AurPASS
  • 34. AurPASS Product Line 07/04/2011 26 AurPASS Application Note and Evaluation Software available Under Request May, 2011 AurPASS Off-Targets AurPASS GPCR AurPASS Nuclear Receptors
  • 35. Thank you for your attention Aureus Sciences 174, Quai de Jemmapes 75010 Paris, FRANCE www.aureus-pharma.com 07/04/2011 27 AurPASS